{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T18:13:56Z","timestamp":1783188836015,"version":"3.54.6"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00702-023-02684-9","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T10:01:55Z","timestamp":1692612115000},"page":"1451-1462","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson\u2019s disease: clinical and therapeutic considerations"],"prefix":"10.1007","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0060-9935","authenticated-orcid":false,"given":"Onanong","family":"Phokaewvarangkul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6901-2064","authenticated-orcid":false,"given":"Roongroj","family":"Bhidayasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6194-672X","authenticated-orcid":false,"given":"Pedro","family":"Garcia-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0756-7478","authenticated-orcid":false,"given":"Per","family":"Odin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0520-0373","authenticated-orcid":false,"given":"Peter","family":"Riederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8096-1853","authenticated-orcid":false,"given":"Thomas","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,21]]},"reference":[{"key":"2684_CR1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1179\/174313211X12966635733312","volume":"14","author":"E Aden","year":"2011","unstructured":"Aden E, Carlsson M, Poortvliet E, Stenlund H, Linder J, Edstrom M, Forsgren L, Haglin L (2011) Dietary intake and olfactory function in patients with newly diagnosed Parkinson\u2019s disease: a case-control study. Nutr Neurosci 14:25\u201331","journal-title":"Nutr Neurosci"},{"key":"2684_CR2","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jocn.2021.03.047","volume":"88","author":"C Anamnart","year":"2021","unstructured":"Anamnart C, Kitjarak R (2021) Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson\u2019s disease patients: a randomized controlled study. J Clin Neurosci 88:226\u2013231","journal-title":"J Clin Neurosci"},{"key":"2684_CR3","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.euroneuro.2010.04.010","volume":"20","author":"A Antonini","year":"2010","unstructured":"Antonini A, Bondiolotti G, Natuzzi F, Bareggi SR (2010) Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa. Eur Neuropsychopharmacol 20:683\u2013687","journal-title":"Eur Neuropsychopharmacol"},{"key":"2684_CR4","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.nrl.2021.10.002","volume":"37","author":"R Baviera-Munoz","year":"2022","unstructured":"Baviera-Munoz R, Buigues-Lafuente A, Campins-Romeu M, Garces-Sanchez M, Martinez-Torres I (2022) Refractory status epilepticus due to vitamin B(6) deficit in a Parkinson\u2019s disease patient in treatment with levodopa\/carbidopa intestinal gel. Neurologia (engl Ed) 37:608\u2013609","journal-title":"Neurologia (engl Ed)"},{"key":"2684_CR5","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1468-1331.2009.02894.x","volume":"17","author":"V Belcastro","year":"2010","unstructured":"Belcastro V, Pierguidi L, Castrioto A, Menichetti C, Gorgone G, Ientile R, Pisani F, Rossi A, Calabresi P, Tambasco N (2010) Hyperhomocysteinemia recurrence in levodopa-treated Parkinson\u2019s disease patients. Eur J Neurol 17:661\u2013665","journal-title":"Eur J Neurol"},{"key":"2684_CR6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/jnnp.58.3.293","volume":"58","author":"Y Ben Shlomo","year":"1995","unstructured":"Ben Shlomo Y, Marmot MG (1995) Survival and cause of death in a cohort of patients with parkinsonism: Possible clues to aetiology? J Neurol Neurosurg Psychiatry 58:293\u2013299","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2684_CR7","first-page":"272","volume":"43","author":"M Bialecka","year":"2009","unstructured":"Bialecka M, Robowski P, Honczarenko K, Roszmann A, Slawek J (2009) Genetic and environmental factors for hyperhomocysteinaemia and its clinical implications in Parkinson\u2019s disease. Neurol Neurochir Pol 43:272\u2013285","journal-title":"Neurol Neurochir Pol"},{"key":"2684_CR8","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/advances\/nmab060","volume":"12","author":"JT Boelens Keun","year":"2021","unstructured":"Boelens Keun JT, Arnoldussen IA, Vriend C, Van De RO (2021) Dietary approaches to improve efficacy and control side effects of levodopa therapy in Parkinson\u2019s disease: a systematic review. Adv Nutr 12:2265\u20132287","journal-title":"Adv Nutr"},{"key":"2684_CR9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/archneur.1978.00500330029005","volume":"35","author":"MI Botez","year":"1978","unstructured":"Botez MI, Peyronnard JM, Bachevalier J, Charron L (1978) Polyneuropathy and folate deficiency. Arch Neurol 35:581\u2013584","journal-title":"Arch Neurol"},{"issue":"2","key":"2684_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2165\/00003495-199448020-00002","volume":"48","author":"T Bottiglieri","year":"1994","unstructured":"Bottiglieri T, Hyland K, Reynolds EH (1994) The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs 48(2):137\u2013152. https:\/\/doi.org\/10.2165\/00003495-199448020-00002","journal-title":"Drugs"},{"key":"2684_CR11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.18388\/abp.2004_3580","volume":"51","author":"JT Brosnan","year":"2004","unstructured":"Brosnan JT, Jacobs RL, Stead LM, Brosnan ME (2004) Methylation demand: a key determinant of homocysteine metabolism. Acta Biochim Pol 51:405\u2013413","journal-title":"Acta Biochim Pol"},{"issue":"10","key":"2684_CR12","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/mds.25585","volume":"28","author":"R Ceravolo","year":"2013","unstructured":"Ceravolo R, Cossu G, Bandettini di Poggio M, Santoro L, Barone P, Zibetti M, Frosini D, Nicoletti V, Manganelli F, Iodice R, Picillo M, Merola A, Lopiano L, Paribello A, Manca D, Melis M, Marchese R, Borelli P, Mereu A, Contu P, Abbruzzese G, Bonuccelli U (2013) Neuropathy and levodopa in Parkinson\u2019s disease: evidence from a multicenter study. Mov Disord 28(10):1391\u20131397. https:\/\/doi.org\/10.1002\/mds.25585","journal-title":"Mov Disord"},{"key":"2684_CR13","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/aje\/kwh213","volume":"160","author":"H Chen","year":"2004","unstructured":"Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Logroscino G, Willett WC, Ascherio A (2004) Folate intake and risk of Parkinson\u2019s disease. Am J Epidemiol 160:368\u2013375","journal-title":"Am J Epidemiol"},{"key":"2684_CR14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.parkreldis.2020.12.026","volume":"83","author":"YJ Choi","year":"2021","unstructured":"Choi YJ, Choi IY, Jang W, Jeong SM, Park S, Han K, Lee Y, Lee DH, Shin DW (2021) Gastrectomy, vitamin B12 supplementation and the risk of Parkinson\u2019s disease: a nationwide cohort study. Parkinsonism Relat Disord 83:15\u201321","journal-title":"Parkinsonism Relat Disord"},{"key":"2684_CR15","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/mds.27301","volume":"33","author":"CW Christine","year":"2018","unstructured":"Christine CW, Auinger P, Joslin A, Yelpaala Y, Green R (2018) Vitamin B12 and homocysteine levels predict different outcomes in early Parkinson\u2019s disease. Mov Disord 33:762\u2013770","journal-title":"Mov Disord"},{"key":"2684_CR16","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/mds.28073","volume":"35","author":"CW Christine","year":"2020","unstructured":"Christine CW, Auinger P, Saleh N, Tian M, Bottiglieri T, Arning E, Tran NK, Ueland PM, Green R (2020) Relationship of cerebrospinal fluid vitamin B12 status markers with Parkinson\u2019s disease progression. Mov Disord 35:1466\u20131471","journal-title":"Mov Disord"},{"key":"2684_CR17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1212\/01.wnl.0000225050.57553.6d","volume":"67","author":"LM de Lau","year":"2006","unstructured":"de Lau LM, Koudstaal PJ, Witteman JC, Hofman A, Breteler MM (2006) Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology 67:315\u2013318","journal-title":"Neurology"},{"key":"2684_CR18","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K (2004) Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med 351:2498\u20132508","journal-title":"N Engl J Med"},{"issue":"11","key":"2684_CR19","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1002\/acn3.51227","volume":"7","author":"X Fan","year":"2020","unstructured":"Fan X, Zhang L, Li H, Chen G, Qi G, Ma X, Jin Y (2020) Role of homocysteine in the development and progression of Parkinson\u2019s disease. Ann Clin Transl Neurol 7(11):2332\u20132338. https:\/\/doi.org\/10.1002\/acn3.51227","journal-title":"Ann Clin Transl Neurol"},{"key":"2684_CR20","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.4103\/aian.aian_38_22","volume":"25","author":"A Goel","year":"2022","unstructured":"Goel A, Narayan SK, Sugumaran R (2022) Neuropsychiatric features, health-related quality of life, and caregiver burden in Parkinson\u2019s disease. Ann Indian Acad Neurol 25:1147\u20131152","journal-title":"Ann Indian Acad Neurol"},{"key":"2684_CR21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/ejcn.2016.181","volume":"71","author":"L Haglin","year":"2017","unstructured":"Haglin L, Johansson I, Forsgren L, Backman L (2017) Intake of vitamin B before onset of Parkinson\u2019s disease and atypical parkinsonism and olfactory function at the time of diagnosis. Eur J Clin Nutr 71:97\u2013102","journal-title":"Eur J Clin Nutr"},{"key":"2684_CR22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/01.WNF.0000236763.16032.60","volume":"29","author":"S Hassin-Baer","year":"2006","unstructured":"Hassin-Baer S, Cohen O, Vakil E, Sela BA, Nitsan Z, Schwartz R, Chapman J, Tanne D (2006) Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications. Clin Neuropharmacol 29:305\u2013311","journal-title":"Clin Neuropharmacol"},{"key":"2684_CR23","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jocn.2009.09.034","volume":"17","author":"C Isobe","year":"2010","unstructured":"Isobe C, Abe T, Terayama Y (2010) L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson\u2019s disease. J Clin Neurosci 17:717\u2013721","journal-title":"J Clin Neurosci"},{"key":"2684_CR24","doi-asserted-by":"crossref","first-page":"e66639","DOI":"10.1371\/journal.pone.0066639","volume":"8","author":"C Jugel","year":"2013","unstructured":"Jugel C, Ehlen F, Taskin B, Marzinzik F, Muller T, Klostermann F (2013) Neuropathy in Parkinson\u2019s disease patients with intestinal levodopa infusion versus oral drugs. PLoS ONE 8:e66639","journal-title":"PLoS ONE"},{"key":"2684_CR25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00702-011-0689-3","volume":"119","author":"F Klostermann","year":"2012","unstructured":"Klostermann F, Jugel C, Muller T, Marzinzik F (2012) Malnutritional neuropathy under intestinal levodopa infusion. J Neural Transm 119:369\u2013372","journal-title":"J Neural Transm"},{"key":"2684_CR26","doi-asserted-by":"crossref","first-page":"7563705","DOI":"10.1155\/2016\/7563705","volume":"2016","author":"B Kocer","year":"2016","unstructured":"Kocer B, Guven H, Comoglu SS (2016) Homocysteine levels in Parkinson\u2019s disease: Is entacapone effective? Biomed Res Int 2016:7563705","journal-title":"Biomed Res Int"},{"key":"2684_CR27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000007984","volume":"40","author":"W Kuhn","year":"1998","unstructured":"Kuhn W, Roebroek R, Blom H, Van OD, Przuntek H, Kretschmer A, Buttner T, Woitalla D, Muller T (1998) Elevated plasma levels of homocysteine in Parkinson\u2019s disease. Eur Neurol 40:225\u2013227","journal-title":"Eur Neurol"},{"key":"2684_CR28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/mds.20261","volume":"20","author":"P Lamberti","year":"2005","unstructured":"Lamberti P, Zoccolella S, Iliceto G, Armenise E, Fraddosio A, De MM, Livrea P (2005) Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson\u2019s disease patients. Mov Disord 20:69\u201372","journal-title":"Mov Disord"},{"key":"2684_CR29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s00223-009-9327-6","volume":"86","author":"SH Lee","year":"2010","unstructured":"Lee SH, Kim MJ, Kim BJ, Kim SR, Chun S, Kim HK, Ryu JS, Kim GS, Lee MC, Chung SJ, Koh JM (2010) Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson\u2019s disease. Calcif Tissue Int 86:132\u2013141","journal-title":"Calcif Tissue Int"},{"key":"2684_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.parkreldis.2017.08.005","volume":"44","author":"N Licking","year":"2017","unstructured":"Licking N, Murchison C, Cholerton B, Zabetian CP, Hu SC, Montine TJ, Peterson-Hiller AL, Chung KA, Edwards K, Leverenz JB, Quinn JF (2017) Homocysteine and cognitive function in Parkinson\u2019s disease. Parkinsonism Relat Disord 44:1\u20135","journal-title":"Parkinsonism Relat Disord"},{"issue":"11","key":"2684_CR31","doi-asserted-by":"publisher","first-page":"5923","DOI":"10.1073\/pnas.94.11.5923","volume":"94","author":"SA Lipton","year":"1997","unstructured":"Lipton SA, Kim WK, Choi YB, Kumar S, D\u2019Emilia DM, Rayudu PV, Arnelle DR, Stamler JS (1997) Neurotoxicity associated with dual actions of homocysteine at the N-methyl-d-aspartate receptor. Proc Natl Acad Sci U S A 94(11):5923\u20135928. https:\/\/doi.org\/10.1073\/pnas.94.11.5923","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2684_CR32","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1093\/brain\/awac225","volume":"145","author":"KJ Lizarraga","year":"2022","unstructured":"Lizarraga KJ, Lang AE (2022) Vitamins B6 and B12, levodopa, and their complex interactions in patients with Parkinson\u2019s disease. Brain 145:e77\u2013e78","journal-title":"Brain"},{"key":"2684_CR33","doi-asserted-by":"crossref","first-page":"e00698","DOI":"10.1002\/brb3.698","volume":"7","author":"S Loens","year":"2017","unstructured":"Loens S, Chorbadzhieva E, Kleimann A, Dressler D, Schrader C (2017) Effects of levodopa\/carbidopa intestinal gel versus oral levodopa\/carbidopa on B vitamin levels and neuropathy. Brain Behav 7:e00698","journal-title":"Brain Behav"},{"key":"2684_CR34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2007.01.028","volume":"257","author":"E Martignoni","year":"2007","unstructured":"Martignoni E, Tassorelli C, Nappi G, Zangaglia R, Pacchetti C, Blandini F (2007) Homocysteine and Parkinson\u2019s disease: A dangerous liaison? J Neurol Sci 257:31\u201337","journal-title":"J Neurol Sci"},{"key":"2684_CR35","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1007\/s00415-022-11546-5","volume":"270","author":"P Martinez-Martin","year":"2023","unstructured":"Martinez-Martin P, Skorvanek M, Henriksen T, Lindvall S, Domingos J, Alobaidi A, Kandukuri PL, Chaudhari VS, Patel AB, Parra JC, Pike J, Antonini A (2023) Impact of advanced Parkinson\u2019s disease on caregivers: an international real-world study. J Neurol 270:2162\u20132173","journal-title":"J Neurol"},{"key":"2684_CR36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.parkreldis.2020.03.009","volume":"73","author":"SJ McCarter","year":"2020","unstructured":"McCarter SJ, Stang C, Turcano P, Mielke MM, Ali F, Bower JH, Savica R (2020) Higher vitamin B12 level at Parkinson\u2019s disease diagnosis is associated with lower risk of future dementia. Parkinsonism Relat Disord 73:19\u201322","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"2684_CR37","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/cphy.c150021","volume":"6","author":"KS McCully","year":"2015","unstructured":"McCully KS (2015) Homocysteine metabolism, atherosclerosis, and diseases of aging. Compr Physiol 6(1):471\u2013505. https:\/\/doi.org\/10.1002\/cphy.c150021","journal-title":"Compr Physiol"},{"key":"2684_CR38","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/ene.12846","volume":"23","author":"A Merola","year":"2016","unstructured":"Merola A, Romagnolo A, Zibetti M, Bernardini A, Cocito D, Lopiano L (2016) Peripheral neuropathy associated with levodopa\u2013carbidopa intestinal infusion: a long-term prospective assessment. Eur J Neurol 23:501\u2013509","journal-title":"Eur J Neurol"},{"key":"2684_CR39","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1212\/WNL.58.10.1471","volume":"58","author":"JW Miller","year":"2002","unstructured":"Miller JW, Green R, Mungas DM, Reed BR, Jagust WJ (2002) Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology 58:1471\u20131475","journal-title":"Neurology"},{"issue":"8","key":"2684_CR40","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/0026-0495(80)90192-4","volume":"29","author":"SH Mudd","year":"1980","unstructured":"Mudd SH, Ebert MH, Scriver CR (1980) Labile methyl group balances in the human: the role of sarcosine. Metabolism 29(8):707\u2013720. https:\/\/doi.org\/10.1016\/0026-0495(80)90192-4","journal-title":"Metabolism"},{"key":"2684_CR41","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1586\/14737175.8.6.957","volume":"8","author":"T Muller","year":"2008","unstructured":"Muller T (2008) Role of homocysteine in the treatment of Parkinson\u2019s disease. Expert Rev Neurother 8:957\u2013967","journal-title":"Expert Rev Neurother"},{"key":"2684_CR42","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1517\/17425255.2011.575779","volume":"7","author":"T Muller","year":"2011","unstructured":"Muller T (2011) Motor complications, levodopa metabolism and progression of Parkinson\u2019s disease. Expert Opin Drug Metab Toxicol 7:847\u2013855","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2684_CR43","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/14656566.2022.2045275","volume":"23","author":"T Muller","year":"2022","unstructured":"Muller T (2022) What are the main considerations when prescribing pharmacotherapy for Parkinson\u2019s disease? Expert Opin Pharmacother 23:745\u2013750","journal-title":"Expert Opin Pharmacother"},{"key":"2684_CR44","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00228-006-0132-0","volume":"62","author":"T Muller","year":"2006","unstructured":"Muller T, Kuhn W (2006) Tolcapone decreases plasma levels of S-adenosyl-l-homocysteine and homocysteine in treated Parkinson\u2019s disease patients. Eur J Clin Pharmacol 62:447\u2013450","journal-title":"Eur J Clin Pharmacol"},{"key":"2684_CR45","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/mds.22607","volume":"24","author":"T Muller","year":"2009","unstructured":"Muller T, Kuhn W (2009) Homocysteine levels after acute levodopa intake in patients with Parkinson\u2019s disease. Mov Disord 24:1339\u20131343","journal-title":"Mov Disord"},{"key":"2684_CR46","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s00702-009-0275-0","volume":"116","author":"T Muller","year":"2009","unstructured":"Muller T, Muhlack S (2009) Peripheral COMT inhibition prevents levodopa associated homocysteine increase. J Neural Transm 116:1253\u20131256","journal-title":"J Neural Transm"},{"key":"2684_CR47","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0140-6736(99)01660-8","volume":"354","author":"T Muller","year":"1999","unstructured":"Muller T, Werne B, Fowler B, Kuhn W (1999) Nigral endothelial dysfunction, homocysteine, and Parkinson\u2019s disease. Lancet 354:126\u2013127","journal-title":"Lancet"},{"key":"2684_CR48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s007020200013","volume":"109","author":"T Muller","year":"2002","unstructured":"Muller T, Woitalla D, Fowler B, Kuhn W (2002) 3-OMD and homocysteine plasma levels in parkinsonian patients. J Neural Transm 109:175\u2013179","journal-title":"J Neural Transm"},{"key":"2684_CR49","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archneur.61.5.657","volume":"61","author":"T Muller","year":"2004","unstructured":"Muller T, Renger K, Kuhn W (2004) Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch Neurol 61:657\u2013660","journal-title":"Arch Neurol"},{"key":"2684_CR50","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00702-006-0442-5","volume":"113","author":"T Muller","year":"2006","unstructured":"Muller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Goetze O, Woitalla D (2006) Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa\/carbidopa with and without entacapone in patients with Parkinson\u2019s disease. J Neural Transm 113:1441\u20131448","journal-title":"J Neural Transm"},{"key":"2684_CR51","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00702-011-0614-9","volume":"118","author":"T Muller","year":"2011","unstructured":"Muller T, Jugel C, Ehret R, Ebersbach G, Bengel G, Muhlack S, Klostermann F (2011a) Elevation of total homocysteine levels in patients with Parkinson\u2019s disease treated with duodenal levodopa\/carbidopa gel. J Neural Transm 118:1329\u20131333","journal-title":"J Neural Transm"},{"key":"2684_CR52","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00702-011-0614-9","volume":"118","author":"T Muller","year":"2011","unstructured":"Muller T, Jugel C, Ehret R, Ebersbach G, Bengel G, Muhlack S, Klostermann F (2011b) Elevation of total homocysteine levels in patients with Parkinson\u2019s disease treated with duodenal levodopa\/carbidopa gel. J Neural Transm (vienna) 118:1329\u20131333","journal-title":"J Neural Transm (vienna)"},{"key":"2684_CR53","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00210-011-0629-7","volume":"383","author":"T Muller","year":"2011","unstructured":"Muller T, Woitalla D, Muhlack S (2011c) Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson\u2019s disease. Naunyn Schmiedebergs Arch Pharmacol 383:627\u2013633","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2684_CR54","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.parkreldis.2013.02.006","volume":"19","author":"T Muller","year":"2013","unstructured":"Muller T, Van LT, Cornblath DR, Odin P, Klostermann F, Grandas FJ, Ebersbach G, Urban PP, Valldeoriola F, Antonini A (2013) Peripheral neuropathy in Parkinson\u2019s disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord 19:501\u2013507","journal-title":"Parkinsonism Relat Disord"},{"key":"2684_CR55","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/WNF.0b013e318283fa18","volume":"36","author":"T Muller","year":"2013","unstructured":"Muller T, Jugel C, Muhlack S, Klostermann F (2013) Methyl group-donating vitamins elevate 3-O-methyldopa in patients with Parkinson disease. Clin Neuropharmacol 36:52\u201354","journal-title":"Clin Neuropharmacol"},{"key":"2684_CR56","first-page":"1","volume":"11","author":"T Muller","year":"2022","unstructured":"Muller T, Schlegel E, Zingler S, Thiede HM (2022) Effects of one-day application of levodopa\/carbidopa\/entacapone versus levodopa\/carbidopa\/opicapone in Parkinson\u2019s disease patients. Cells 11:1","journal-title":"Cells"},{"key":"2684_CR57","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-510X(02)00353-2","volume":"207","author":"K Nakaso","year":"2003","unstructured":"Nakaso K, Yasui K, Kowa H, Kusumi M, Ueda K, Yoshimoto Y, Takeshima T, Sasaki K, Nakashima K (2003) Hypertrophy of IMC of carotid artery in Parkinson\u2019s disease is associated with L-DOPA, homocysteine, and MTHFR genotype. J Neurol Sci 207:19\u201323","journal-title":"J Neurol Sci"},{"key":"2684_CR58","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.parkreldis.2008.10.005","volume":"15","author":"M Nevrly","year":"2009","unstructured":"Nevrly M, Kanovsky P, Vranova H, Langova K, Hlustik P (2009) Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson\u2019s disease patients. Parkinsonism Relat Disord 15:477\u2013478","journal-title":"Parkinsonism Relat Disord"},{"key":"2684_CR59","first-page":"S72","volume":"55","author":"CW Olanow","year":"2000","unstructured":"Olanow CW, Obeso JA (2000) Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson\u2019s disease: implications for the early use of COMT inhibitors. Neurology 55:S72\u2013S77","journal-title":"Neurology"},{"key":"2684_CR60","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1212\/01.WNL.0000158674.91134.6E","volume":"64","author":"JL Ostrem","year":"2005","unstructured":"Ostrem JL, Kang GA, Subramanian I, Guarnieri M, Hubble J, Rabinowicz AL, Bronstein J (2005) The effect of entacapone on homocysteine levels in Parkinson disease. Neurology 64:1482","journal-title":"Neurology"},{"key":"2684_CR61","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/mds.20253","volume":"19","author":"PE O'Suilleabhain","year":"2004","unstructured":"O\u2019Suilleabhain PE, Bottiglieri T, Dewey RB Jr, Sharma S, Az-Arrastia R (2004) Modest increase in plasma homocysteine follows levodopa initiation in Parkinson\u2019s disease. Mov Disord 19:1403\u20131408","journal-title":"Mov Disord"},{"key":"2684_CR62","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.parkreldis.2005.10.002","volume":"12","author":"PE O'Suilleabhain","year":"2006","unstructured":"O\u2019Suilleabhain PE, Oberle R, Bartis C, Dewey RB Jr, Bottiglieri T, Az-Arrastia R (2006) Clinical course in Parkinson\u2019s disease with elevated homocysteine. Parkinsonism Relat Disord 12:103\u2013107","journal-title":"Parkinsonism Relat Disord"},{"key":"2684_CR63","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1179\/016164106X110445","volume":"28","author":"F Ozer","year":"2006","unstructured":"Ozer F, Meral H, Hanoglu L, Aydemir T, Yilsen M, Cetin S, Ozturk O, Seval H, Koldas M (2006) Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations. Neurol Res 28:853\u2013858","journal-title":"Neurol Res"},{"key":"2684_CR64","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/01.wnf.0000136890.78887.b9","volume":"27","author":"S Ozkan","year":"2004","unstructured":"Ozkan S, Colak O, Kutlu C, Ertan M, Alatas O (2004) Plasma homocysteine levels in pergolide-treated Parkinson disease patients. Clin Neuropharmacol 27:163\u2013165","journal-title":"Clin Neuropharmacol"},{"key":"2684_CR65","doi-asserted-by":"crossref","first-page":"e2408","DOI":"10.1002\/brb3.2408","volume":"11","author":"KAM Pauls","year":"2021","unstructured":"Pauls KAM, Toppila J, Koivu M, Eerola-Rautio J, Udd M, Pekkonen E (2021) Polyneuropathy monitoring in Parkinson\u2019s disease patients treated with levodopa\/carbidopa intestinal gel. Brain Behav 11:e2408","journal-title":"Brain Behav"},{"key":"2684_CR66","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1212\/01.wnl.0000219815.83681.f7","volume":"66","author":"RB Postuma","year":"2006","unstructured":"Postuma RB, Espay AJ, Zadikoff C, Suchowersky O, Martin WR, Lafontaine AL, Ranawaya R, Camicioli R, Lang AE (2006) Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology 66:1941\u20131943","journal-title":"Neurology"},{"key":"2684_CR67","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00702-003-0102-y","volume":"111","author":"H Przuntek","year":"2004","unstructured":"Przuntek H, Muller T, Riederer P (2004) Diagnostic staging of Parkinson\u2019s disease: conceptual aspects. J Neural Transm 111:201\u2013216","journal-title":"J Neural Transm"},{"key":"2684_CR68","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1007\/s00415-013-7079-8","volume":"260","author":"YA Rajabally","year":"2013","unstructured":"Rajabally YA, Martey J (2013) Levodopa, vitamins, ageing and the neuropathy of Parkinson\u2019s disease. J Neurol 260:2844\u20132848","journal-title":"J Neurol"},{"key":"2684_CR69","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.4103\/aian.aian_669_22","volume":"25","author":"A Ramachandran","year":"2022","unstructured":"Ramachandran A, Jose J, Gafoor VA, Das S, Balaram N (2022) Prevalence and risk factors of peripheral neuropathy in Parkinson\u2019s disease. Ann Indian Acad Neurol 25:1109\u20131115","journal-title":"Ann Indian Acad Neurol"},{"key":"2684_CR70","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1093\/jn\/137.7.1789","volume":"137","author":"G Raman","year":"2007","unstructured":"Raman G, Tatsioni A, Chung M, Rosenberg IH, Lau J, Lichtenstein AH, Balk EM (2007) Heterogeneity and lack of good quality studies limit association between folate, vitamins B-6 and B-12, and cognitive function. J Nutr 137:1789\u20131794","journal-title":"J Nutr"},{"key":"2684_CR71","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/ane.12783","volume":"136","author":"V Rispoli","year":"2017","unstructured":"Rispoli V, Simioni V, Capone JG, Golfre AN, Preda F, Sette E, Tugnoli V, Sensi M (2017) Peripheral neuropathy in 30 duodopa patients with vitamins B supplementation. Acta Neurol Scand 136:660\u2013667","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"2684_CR72","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/mdc3.12688","volume":"6","author":"A Romagnolo","year":"2019","unstructured":"Romagnolo A, Merola A, Artusi CA, Rizzone MG, Zibetti M, Lopiano L (2019) Levodopa-induced neuropathy: a systematic review. Mov Disord Clin Pract 6(2):96\u2013103. https:\/\/doi.org\/10.1002\/mdc3.12688","journal-title":"Mov Disord Clin Pract"},{"key":"2684_CR73","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/bs.vh.2022.01.001","volume":"119","author":"P Sahu","year":"2022","unstructured":"Sahu P, Thippeswamy H, Chaturvedi SK (2022) Neuropsychiatric manifestations in vitamin B12 deficiency. Vitam Horm 119:457\u2013470","journal-title":"Vitam Horm"},{"key":"2684_CR74","doi-asserted-by":"crossref","first-page":"120148","DOI":"10.1016\/j.jns.2022.120148","volume":"434","author":"F Sampedro","year":"2022","unstructured":"Sampedro F, Martinez-Horta S, Horta-Barba A, Grothe MJ, Labrador-Espinosa MA, Jesus S, Rmes-Gomez A, Carrillo F, Puig-Davi A, Lora FR, Barbera MA, Pastor P, Arroyo SE, Vila BS, Foraster AC, Martinez JR, Padilla FC, Morlans MP, Aramburu IG, Ceberio JI, Vara JH, de Fabregues-Boixar O, de Deus FT, Avila A, Martinez-Castrillo JC, Bejr-Kasem H, Campolongo A, Pascual-Sedano B, Martinez-Martin P, Santos-Garcia D, Mir P, Kulisevsky J (2022) Increased homocysteine levels correlate with cortical structural damage in Parkinson\u2019s disease. J Neurol Sci 434:120148","journal-title":"J Neurol Sci"},{"key":"2684_CR75","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2217\/nmt-2016-0011","volume":"6","author":"GD Santos","year":"2016","unstructured":"Santos GD, Martinez Castrillo JC, Puente PV, Seoane UA, Fernandez DS, Benita LV, Udaeta BB, Campolongo PA, Mariscal PN (2016) Clinical management of patients with advanced Parkinson\u2019s disease treated with continuous intestinal infusion of levodopa\/carbidopa. Neurodegener Dis Manag 6:187\u2013202","journal-title":"Neurodegener Dis Manag"},{"key":"2684_CR76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/gps.5761","volume":"37","author":"D Santos-Garcia","year":"2022","unstructured":"Santos-Garcia D, de Deus FT, Cores BC, Iniguez Alvarado MC, Feal Panceiras MJ, Suarez CE, Canfield H, Martinez MC, Jesus S, Aguilar M, Pastor P, Planellas L, Cosgaya M, Garcia CJ, Caballol N, Legarda I, Hernandez VJ, Cabo I, Lopez ML, Gonzalez AI, Vila Rivera MA, Gomez MV, Nogueira V, Puente V, Dotor Garcia-Soto J, Borrue C, Solano VB, Alvarez SM, Vela L, Escalante S, Cubo E, Carrillo PF, Martinez Castrillo JC, Sanchez AP, Onso Losada MG, Ariztegui NL, Gaston I, Kulisevsky J, Blazquez EM, Seijo M, Martinez JR, Valero C, Kurtis M, De FO, Gonzalez AJ, Alonso RR, Ordas C, Lopez DiazL LM, McAfee D, Martinez-Martin P, Mir P (2022) Predictors of the change in burden, strain, mood, and quality of life among caregivers of Parkinson\u2019s disease patients. Int J Geriatr Psychiatry 37:1","journal-title":"Int J Geriatr Psychiatry"},{"key":"2684_CR77","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1212\/WNL.62.4.676","volume":"62","author":"K Schroecksnadel","year":"2004","unstructured":"Schroecksnadel K, Leblhuber F, Fuchs D (2004) Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 62:676\u2013677","journal-title":"Neurology"},{"key":"2684_CR78","doi-asserted-by":"crossref","first-page":"7197","DOI":"10.3390\/nu7095333","volume":"7","author":"L Shen","year":"2015","unstructured":"Shen L (2015) Associations between B vitamins and Parkinson\u2019s disease. Nutrients 7:7197\u20137208","journal-title":"Nutrients"},{"issue":"8","key":"2684_CR79","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/prot.25681","volume":"87","author":"Y Silla","year":"2019","unstructured":"Silla Y, Varshney S, Ray A, Basak T, Zinellu A, Sabareesh V, Carru C, Sengupta S (2019) Hydrolysis of homocysteine thiolactone results in the formation of protein-cys-S-S-homocysteinylation. Proteins 87(8):625\u2013634. https:\/\/doi.org\/10.1002\/prot.25681","journal-title":"Proteins"},{"issue":"2","key":"2684_CR80","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00702-012-0856-1","volume":"120","author":"S Skodda","year":"2013","unstructured":"Skodda S, Muller T (2013) Refractory epileptic seizures due to vitamin B6 deficiency in a patient with Parkinson\u2019s disease under duodopa(R) therapy. J Neural Transm (vienna) 120(2):315\u2013318. https:\/\/doi.org\/10.1007\/s00702-012-0856-1","journal-title":"J Neural Transm (vienna)"},{"key":"2684_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17101733","author":"H Skovierova","year":"2016","unstructured":"Skovierova H, Vidomanova E, Mahmood S, Sopkova J, Drgova A, Cervenova T, Halasova E, Lehotsky J (2016) The molecular and cellular effect of homocysteine metabolism imbalance on human health. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms17101733","journal-title":"Int J Mol Sci"},{"key":"2684_CR82","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.archger.2013.04.015","volume":"57","author":"IU Song","year":"2013","unstructured":"Song IU, Kim JS, Park IS, Kim YD, Cho HJ, Chung SW, Lee KS (2013) Clinical significance of homocysteine (hcy) on dementia in Parkinson\u2019s disease (PD). Arch Gerontol Geriatr 57:288\u2013291","journal-title":"Arch Gerontol Geriatr"},{"key":"2684_CR83","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1017\/cjn.2021.78","volume":"49","author":"J Taher","year":"2022","unstructured":"Taher J, Naranian T, Poon YY, Merola A, Mestre T, Suchowersky O, Kulasingam V, Fasano A (2022) Vitamins and infusion of levodopa\u2013carbidopa intestinal gel. Can J Neurol Sci 49:19\u201328","journal-title":"Can J Neurol Sci"},{"key":"2684_CR84","first-page":"1","volume":"14","author":"H Takeuchi","year":"2022","unstructured":"Takeuchi H, Kawashima R (2022) A prospective study on the relationship between iron supplement intake, hemoglobin concentration, and risk of Parkinsonism. Nutrients 14:1","journal-title":"Nutrients"},{"key":"2684_CR85","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3233\/JAD-2006-9408","volume":"9","author":"F Tchantchou","year":"2006","unstructured":"Tchantchou F (2006) Homocysteine metabolism and various consequences of folate deficiency. J Alzheimers Dis 9:421\u2013427","journal-title":"J Alzheimers Dis"},{"issue":"13","key":"2684_CR86","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1002\/mds.22137","volume":"23","author":"C Toth","year":"2008","unstructured":"Toth C, Brown MS, Furtado S, Suchowersky O, Zochodne D (2008) Neuropathy as a potential complication of levodopa use in Parkinson\u2019s disease. Mov Disord 23(13):1850\u20131859. https:\/\/doi.org\/10.1002\/mds.22137","journal-title":"Mov Disord"},{"key":"2684_CR87","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ana.22021","volume":"68","author":"C Toth","year":"2010","unstructured":"Toth C, Breithaupt K, Ge S, Duan Y, Terris JM, Thiessen A, Wiebe S, Zochodne DW, Suchowersky O (2010) Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol 68:28\u201336","journal-title":"Ann Neurol"},{"issue":"9","key":"2684_CR88","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1093\/clinchem\/39.9.1764","volume":"39","author":"PM Ueland","year":"1993","unstructured":"Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH (1993) Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 39(9):1764\u20131779","journal-title":"Clin Chem"},{"key":"2684_CR89","doi-asserted-by":"crossref","unstructured":"Ulrey CL, Liu L, Andrews LG, Tollefsbol TO (2005) The impact of metabolism on DNA methylation. Hum Mol Genet 14 Spec No 1: R139-R147","DOI":"10.1093\/hmg\/ddi100"},{"key":"2684_CR90","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.parkreldis.2005.01.007","volume":"11","author":"P Valkovic","year":"2005","unstructured":"Valkovic P, Benetin J, Blazicek P, Valkovicova L, Gmitterova K, Kukumberg P (2005) Reduced plasma homocysteine levels in levodopa\/entacapone treated Parkinson patients. Parkinsonism Relat Disord 11:253\u2013256","journal-title":"Parkinsonism Relat Disord"},{"key":"2684_CR91","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s12603-015-0573-1","volume":"19","author":"M Vikdahl","year":"2015","unstructured":"Vikdahl M, Domellof ME, Forsgren L, Haglin L (2015) Olfactory function, eating ability, and visceral obesity associated with MMSE three years after Parkinson\u2019s disease diagnosis. J Nutr Health Aging 19:894\u2013900","journal-title":"J Nutr Health Aging"},{"key":"2684_CR92","first-page":"1314","volume":"28","author":"D Weintraub","year":"2022","unstructured":"Weintraub D, Irwin D (2022) Diagnosis and treatment of cognitive and neuropsychiatric symptoms in Parkinson disease and dementia with lewy bodies. Continuum (minneap Minn) 28:1314\u20131332","journal-title":"Continuum (minneap Minn)"},{"key":"2684_CR93","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.WNF.0000220817.94102.95","volume":"29","author":"TA Zesiewicz","year":"2006","unstructured":"Zesiewicz TA, Wecker L, Sullivan KL, Merlin LR, Hauser RA (2006) The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status. Clin Neuropharmacol 29:106\u2013111","journal-title":"Clin Neuropharmacol"},{"key":"2684_CR94","doi-asserted-by":"crossref","first-page":"e19333","DOI":"10.1371\/journal.pone.0019333","volume":"6","author":"L Zhang","year":"2011","unstructured":"Zhang L, Yan J, Xu Y, Long L, Zhu C, Chen X, Jiang Y, Yang L, Bian L, Wang Q (2011) The combination of homocysteine and C-reactive protein predicts the outcomes of Chinese patients with Parkinson\u2019s disease and vascular parkinsonism. PLoS ONE 6:e19333","journal-title":"PLoS ONE"},{"key":"2684_CR95","doi-asserted-by":"crossref","first-page":"4797861","DOI":"10.1155\/2022\/4797861","volume":"2022","author":"M Zhong","year":"2022","unstructured":"Zhong M, Zhu S, Gu R, Wang Y, Jiang Y, Bai Y, Jiang X, Shen B, Yan J, Pan Y, Zhu J, Zhang L (2022) Elevation of plasma homocysteine and minor hallucinations in Parkinson\u2019s disease: a cross-sectional study. Behav Neurol 2022:4797861","journal-title":"Behav Neurol"},{"key":"2684_CR96","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.parkreldis.2004.07.008","volume":"11","author":"S Zoccolella","year":"2005","unstructured":"Zoccolella S, Lamberti P, Armenise E, De MM, Lamberti SV, Mastronardi R, Fraddosio A, Iliceto G, Livrea P (2005a) Plasma homocysteine levels in Parkinson\u2019s disease: role of antiparkinsonian medications. Parkinsonism Relat Disord 11:131\u2013133","journal-title":"Parkinsonism Relat Disord"},{"key":"2684_CR97","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1515\/CCLM.2005.193","volume":"43","author":"S Zoccolella","year":"2005","unstructured":"Zoccolella S, Lamberti P, Iliceto G, Diroma C, Armenise E, Defazio G, Lamberti SV, Fraddosio A, De MM, Livrea P (2005b) Plasma homocysteine levels in L-dopa-treated Parkinson\u2019s disease patients with cognitive dysfunctions. Clin Chem Lab Med 43:1107\u20131110","journal-title":"Clin Chem Lab Med"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-023-02684-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-023-02684-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-023-02684-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T09:07:13Z","timestamp":1699952833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-023-02684-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,21]]},"references-count":97,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2684"],"URL":"https:\/\/doi.org\/10.1007\/s00702-023-02684-9","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,21]]},"assertion":[{"value":"5 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors do not have any conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study does not be required consent to participate due to its nature of being a review article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This study does not require consent to publish due to its nature of being review article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data and\/or code availability"}},{"value":"This study does not be required traditional ethical approval or follow the ethical guidelines due to its nature of being a review article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}